Accéder au contenu
MilliporeSigma
Toutes les photos(1)

Principaux documents

Voir toute la documentation

SML3015

Sigma-Aldrich

Arimoclomol maleate

≥98% (HPLC)

Synonyme(s) :

(+)-(R)-N-[2-Hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboximidoyl chloride, maleate salt, (R)-3-(Chloro(2-hydroxy-3-(piperidin-1-yl)propoxyimino)methyl)pyridine 1-oxide, maleate salt, Anti-neurodegeneration agent 1, BRX 220, BRX-220, BRX220, N-[(2R)-2-Hydroxy-3-(1-piperidinyl)propoxy]-3-pyridinecarboximidoyl chloride 1-oxide, maleate salt, maleate salt

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C14H20ClN3O3 · C4H4O4
Numéro CAS:
289893-26-1
Poids moléculaire :
429.85
Numéro MDL:
MFCD28143527
Code UNSPSC :
12352200
Nomenclature NACRES :
NA.77

Niveau de qualité

100

Essai

≥98% (HPLC)

Forme

powder

Couleur

white to beige

Solubilité

H2O: 2 mg/mL, clear

Température de stockage

2-8°C

Chaîne SMILES 

Cl/C(C1=CC=C[N+]([O-])=C1)=N\OC[C@@H](CN2CCCCC2)O.O=C(O)/C=C\C(O)=O

InChI

1S/C14H20ClN3O3.C4H4O4/c15-14(12-5-4-8-18(20)9-12)16-21-11-13(19)10-17-6-2-1-3-7-17;5-3(6)1-2-4(7)8/h4-5,8-9,13,19H,1-3,6-7,10-11H2;1-2H,(H,5,6)(H,7,8)/b;2-1-/t13-;/m1./s1

Clé InChI

OHUSJUJCPWMZKR-FEGZNKODSA-N

Actions biochimiques/physiologiques

Arimoclomol is an orally available, CNS-penetrant coinducer of heat shock proteins (HSPs), notably HSP70, that exhibits in vivo efficay in disease models of diabetes, Gaucher disease (GD), sporadic inclusion body myositis (sIBM), and neurological disorders, including amyotrophic lateral sclerosis (ALS) and Niemann-Pick disease type C1 (NPC1). Note: arimoclomol maleate and citrate salt forms are known as BRX-220 and BRX-345, respectively.
Orally available, CNS-penetrant coinducer of heat shock proteins (HSPs), notably HSP70 (HSP72), with in vivo ALS, GD, NPC1, and sIBM therapeutic efficacy.

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number
0000191677
0000203468

Vous ne trouvez pas la bonne version ?

Si vous avez besoin d'une version particulière, vous pouvez rechercher un certificat spécifique par le numéro de lot.

Rechercher un(e) COA

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Dairin Kieran et al.
Nature medicine, 10(4), 402-405 (2004-03-23)
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative condition in which motoneurons of the spinal cord and motor cortex die, resulting in progressive paralysis. This condition has no cure and results in eventual death, usually within 1-5 years of diagnosis.
B Kalmar et al.
Experimental neurology, 176(1), 87-97 (2002-07-03)
Heat shock proteins (hsps) are induced in a variety of cells following periods of stress, where they promote cell survival. In this study, we examined the effect of upregulating hsp expression by treatment with BRX-220, a co-inducer of hsps, on
Zoltán Rakonczay et al.
Free radical biology & medicine, 32(12), 1283-1292 (2002-06-12)
Nontoxic heat shock protein (HSP) inducer compounds open up promising therapeutic possibilities by activating one of the natural and highly conserved defense mechanisms of the organism. In the present experiments, we examined the effects of a HSP coinducer drug-candidate, BRX-220
Bernadett Kalmar et al.
Journal of neurochemistry, 107(2), 339-350 (2008-08-05)
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by motoneuron degeneration, resulting in muscle paralysis and death, typically within 1-5 years of diagnosis. Although the pathogenesis of ALS remains unclear, there is evidence for the involvement of proteasome
Maria Kürthy et al.
Annals of the New York Academy of Sciences, 967, 482-489 (2002-06-25)
Bimoclomol (BML), a symptomatic antidiabetic agent, has been developed by Biorex R & D Co. to treat diabetic neuropathy and retinopathy. BRX-220, an orally active member of the BRX family, has been developed to treat diabetic complications and insulin resistance
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique